Singapore - engelsk - HSA (Health Sciences Authority)

cyberland consultancy pte. ltd. - general hospital - the primary purpose of this product is for performing data logging and attendance recording. the data would include a person's identification number (read using barcode scanner or nfc tag reader), current body temperature and day-time information. these data can be transmitted immediately or stored within the device for delayed transmission. data is transmitted wirelessly to another device via bluetooth hid or nfc communication. for body temperature measurement, the product uses medical grade ir sensor to perform the task as accurately as possible. primary use of the thermometer function is for screening purposes. for clinical diagnostic purposes, a device that measures core temperature should be used.

Canada - engelsk - Health Canada

laboratoires clarins - octinoxate; octocrylene; oxybenzone; octisalate - spray - 7.5g; 7g; 5g; 5g - octinoxate 7.5g; octocrylene 7g; oxybenzone 5g; octisalate 5g - sunscreen agents

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - fexofenadine hydrochloride 6 mg/ml; fexofenadine hydrochloride 6 mg/ml - oral suspension - 6 mg/ml - active: fexofenadine hydrochloride 6 mg/ml excipient: butyl hydroxybenzoate dibasic sodium phosphate heptahydrate disodium edetate monobasic sodium phosphate monohydrate poloxamer propyl hydroxybenzoate propylene glycol purified water raspberry flavour f-9950 pfc sucrose titanium dioxide xanthan gum xylitol active: fexofenadine hydrochloride 6 mg/ml excipient: dibasic sodium phosphate heptahydrate disodium edetate monobasic sodium phosphate monohydrate poloxamer potassium sorbate propylene glycol purified water raspberry flavour f-9950 pfc sucrose titanium dioxide xanthan gum xylitol - relief of symptoms associated with seasonal allergic rhinitis and allergic rhinitis in adults and children from 2 years of age.

USA - engelsk - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin anhydrous 600 mg in 5 ml - amoxicillin and clavulanate potassium for oral suspension, 600 mg/42.9 mg per 5 ml is indicated for the treatment of pediatric patients with - recurrent or persistent acute otitis media due to s. pneumoniae (penicillin mics less than or equal to 2 mcg/ml), h. influenzae (including β-lactamase–producing strains), or m. catarrhalis (including β-lactamase–producing strains) characterized by the following risk factors: - antibacterial drug exposure for acute otitis media within the preceding 3 months, and either of the following: 1) age 2 years, or younger or 2) day care attendance [see microbiology (12.4)] . limitations of use acute otitis media due to s. pneumoniae alone can be treated with amoxicillin. amoxicillin and clavulanate potassium for oral suspension, 600 mg/42.9 mg per 5 ml is not indicated for the treatment of acute otitis media due to s. pneumoniae with penicillin mic greater than or equal to 4 mcg/ml. therapy may be instituted prior to obtaining the results from bacteriological studies when t

USA - engelsk - NLM (National Library of Medicine)

dr reddys laboratories inc - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin anhydrous 600 mg in 5 ml - augmentin es-600 powder for oral suspension is indicated for the treatment of pediatric patients with recurrent or persistent acute otitis media due to s. pneumoniae (penicillin mics ≤ 2 mcg/ml), h. influenzae (including β-lactamase–producing strains), or m. catarrhalis (including β-lactamase–producing strains) characterized by the following risk factors: - antibiotic exposure for acute otitis media within the preceding 3 months, and either of the following: age ≤ 2 years daycare attendance - age ≤ 2 years - daycare attendance [see clinical pharmacology, microbiology.] note: acute otitis media due to s. pneumoniae alone can be treated with amoxicillin. augmentin es-600 powder for oral suspension is not indicated for the treatment of acute otitis media due to s. pneumoniae with penicillin mic ≥ 4 mcg/ml. therapy may be instituted prior to obtaining the

USA - engelsk - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin anhydrous 600 mg in 5 ml - amoxicillin and clavulanate potassium for oral suspension, 600 mg/42.9 mg per 5 ml is indicated for the treatment of pediatric patients with recurrent or persistent acute otitis media due to s. pneumoniae (penicillin mics ≤2 mcg/ml), h. influenzae (including β-lactamase–producing strains), or m. catarrhalis (including β-lactamase–producing strains) characterized by the following risk factors: - antibiotic exposure for acute otitis media within the preceding 3 months, and either of the following: – age ≤2 years – daycare attendance - – age ≤2 years - – daycare attendance [see clinical pharmacology, microbiology.] note: acute otitis media due to s. pneumoniae alone can be treated with amoxicillin. amoxicillin and clavulanate potassium for oral suspension, 600 mg/42.9 mg per 5 ml is not indicated for the treatment of acute otitis media due to s. pneumoniae with penicillin mic ≥4 mcg/ml. therapy may be instituted prior to obtaining the results from bacteriological studies when there is reason to believe th

USA - engelsk - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin 600 mg in 5 ml - amoxicillin and clavulanate potassium for oral suspension 600 mg/42.9 mg per 5 ml is indicated for the treatment of pediatric patients with - recurrent or persistent acute otitis media due to s. pneumoniae (penicillin mics less than or equal to 2 mcg/ml), h. influenzae (including β-lactamase-producing strains), or m. catarrhalis (including β-lactamase-producing strains) characterized by the following risk factors: -antibacterial drug exposure for acute otitis media within the preceding 3 months, and either of the following: 1) age 2 years, or younger or 2) day care attendance [see microbiology (12.4)] . limitations of use acute otitis media due to s. pneumoniae alone can be treated with amoxicillin. amoxicillin and clavulanate potassium for oral suspension 600 mg/42.9 mg per 5 ml is not indicated for the treatment of acute otitis media due to s. pneumoniae with penicillin mic greater than or equal to 4 mcg/ml. therapy may be instituted prior to obtaining the results from bacteriological studies when t

USA - engelsk - NLM (National Library of Medicine)

hikma pharmaceutical - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin anhydrous 600 mg in 5 ml - amoxicillin and clavulanate potassium for oral suspension, 600 mg/42.9 mg per 5 ml is indicated for the treatment of pediatric patients with recurrent or persistent acute otitis media due to s. pneumoniae (penicillin mics ≤ 2 mcg/ml), h. influenzae (including β-lactamase–producing strains), or m. catarrhalis (including β-lactamase–producing strains) characterized by the following risk factors: - antibiotic exposure for acute otitis media within the preceding 3 months, and either of the following: age ≤ 2 years daycare attendance - age ≤ 2 years - daycare attendance [see clinical pharmacology, microbiology.] note : acute otitis media due to s. pneumoniae alone can be treated with amoxicillin. amoxicillin and clavulanate potassium for oral suspension 600 mg/42.9 mg per 5 ml is not indicated for the treatment of acute otitis media due to s. pneumoniae with penicillin mic ≥ 4 mcg/ml. therapy may be instituted prior to obtaining the results from bacteriological studies when there is reason to believe the infe

USA - engelsk - NLM (National Library of Medicine)

ranbaxy pharmaceuticals inc. - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin and clavulanate potassium for oral suspension, usp, 600 mg/42.9 mg per 5 ml is indicated for the treatment of pediatric patients with recurrent or persistent acute otitis media due to s. pneumoniae (penicillin mics ≤ 2mcg/ml), h. influenzae (including β-lactamase-producing strains), or m. catarrhalis (including b-lactamase-producing strains) characterized by the following risk factors: - antibiotic exposure for acute otitis media within the preceding 3 months, and either of the following: age ≤ 2 years daycare attendance - age ≤ 2 years - daycare attendance [see clinical pharmacology , microbiology ]. note: acute otitis media due to s. pneumoniae alone can be treated with amoxicillin. amoxicillin and clavulanate potassium for oral suspension, usp, 600 mg/42.9 mg per 5 ml is not indicated for the treatment of acute otitis media due to s. pneumoniae with penicillin mic ≥ 4 mcg/ml. therapy may be instituted prior to obtaining results from bacteriological studies when there is reason to believe

USA - engelsk - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - amoxicillin (unii: 804826j2hu) (amoxicillin anhydrous - unii:9em05410q9), clavulanate potassium (unii: q42omw3at8) (clavulanic acid - unii:23521w1s24) - amoxicillin and clavulanate potassium 600 mg/42.9 mg per 5 ml is indicated for the treatment of pediatric patients with recurrent or persistent acute otitis media due to s. pneumoniae (penicillin mics ≤ 2 mcg/ml), h. influenzae (including β-lactamase–producing strains), or m. catarrhalis (including β-lactamase–producing strains) characterized by the following risk factors: - antibiotic exposure for acute otitis media within the preceding 3 months, and either of the following: age ≤ 2 years daycare attendance - age ≤ 2 years - daycare attendance [see clinical pharmacology, microbiology.] note: acute otitis media due to s. pneumoniae alone can be treated with amoxicillin. amoxicillin and clavulanate potassium 600 mg/42.9 mg per 5 ml is not indicated for the treatment of acute otitis media due to s. pneumoniae wit